Skip to main content

Table 6 Chemotherapy details

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Cycles

Cetuximab + CCRT

(n = 62)

CCRT

(n = 124)

Triweekly regimen

 1

1 (1.6%)

0 (0.0%)

 2

28 (45.2%)

50 (40.3%)

 3

10 (16.1%)

14 (11.3%)

Weekly regimen

 4

1 (1.6%)

4 (3.2%)

 5

4 (6.5%)

16 (12.9%)

 6

16 (25.8%)

31 (25%)

 7

2 (3.2%)

9 (7.3%)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us